All three efficacy end points met the prespecified noninferiority margin of @ percentage points for oritavancin versus vancomycin : primary end point , @ % versus @ % ( @ % confidence interval -LSB- CI -RSB- for the difference , -@ to @ percentage points ) ; investigator-assessed clinical cure , @ % versus @ % ( @ % CI for the difference , -@ to @ percentage points ) ; and proportion of patients with a reduction in lesion area of @ % or more , @ % versus @ % ( @ % CI for the difference , -@ to @ percentage points ) .